188 related articles for article (PubMed ID: 15657349)
1. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.
Mohammad RM; Wang S; Aboukameel A; Chen B; Wu X; Chen J; Al-Katib A
Mol Cancer Ther; 2005 Jan; 4(1):13-21. PubMed ID: 15657349
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
[TBL] [Abstract][Full Text] [Related]
3. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
4. Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.
Sun Y; Wu J; Aboukameel A; Banerjee S; Arnold AA; Chen J; Nikolovska-Coleska Z; Lin Y; Ling X; Yang D; Wang S; Al-Katib A; Mohammad RM
Cancer Biol Ther; 2008 Sep; 7(9):1418-26. PubMed ID: 18769131
[TBL] [Abstract][Full Text] [Related]
5. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.
Mohammad RM; Al-Katib A; Aboukameel A; Doerge DR; Sarkar F; Kucuk O
Mol Cancer Ther; 2003 Dec; 2(12):1361-8. PubMed ID: 14707277
[TBL] [Abstract][Full Text] [Related]
6. Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line.
Mohammad RM; Wang S; Banerjee S; Wu X; Chen J; Sarkar FH
Pancreas; 2005 Nov; 31(4):317-24. PubMed ID: 16258364
[TBL] [Abstract][Full Text] [Related]
7. Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells.
Li ZM; Jiang WQ; Zhu ZY; Zhu XF; Zhou JM; Liu ZC; Yang DJ; Guang ZZ
Cancer Biol Ther; 2008 Jan; 7(1):51-60. PubMed ID: 17938578
[TBL] [Abstract][Full Text] [Related]
8. Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model.
Arnold AA; Aboukameel A; Chen J; Yang D; Wang S; Al-Katib A; Mohammad RM
Mol Cancer; 2008 Feb; 7():20. PubMed ID: 18275607
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor.
Levi E; Zhang L; Aboukameel A; Rishi S; Mohammad RM; Polin L; Hatfield JS; Rishi AK
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1401-13. PubMed ID: 20809119
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
11. ApoG2 inhibits antiapoptotic Bcl-2 family proteins and induces mitochondria-dependent apoptosis in human lymphoma U937 cells.
Sun J; Li ZM; Hu ZY; Lin XB; Zhou NN; Xian LJ; Yang DJ; Jiang WQ
Anticancer Drugs; 2008 Nov; 19(10):967-74. PubMed ID: 18827561
[TBL] [Abstract][Full Text] [Related]
12. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
[TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo.
Lin J; Wu Y; Yang D; Zhao Y
Oncol Rep; 2013 Aug; 30(2):731-8. PubMed ID: 23708869
[TBL] [Abstract][Full Text] [Related]
14. I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.
Al-Katib A; Arnold AA; Aboukameel A; Sosin A; Smith P; Mohamed AN; Beck FW; Mohammad RM
Mol Cancer; 2010 Sep; 9():228. PubMed ID: 20809973
[TBL] [Abstract][Full Text] [Related]
15. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
Paoluzzi L; Gonen M; Gardner JR; Mastrella J; Yang D; Holmlund J; Sorensen M; Leopold L; Manova K; Marcucci G; Heaney ML; O'Connor OA
Blood; 2008 Jun; 111(11):5350-8. PubMed ID: 18292288
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma.
Shivakumar L; Armitage JO
Clin Lymphoma Myeloma; 2006 May; 6(6):455-7. PubMed ID: 16796775
[TBL] [Abstract][Full Text] [Related]
17. Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2.
Lei X; Chen Y; Du G; Yu W; Wang X; Qu H; Xia B; He H; Mao J; Zong W; Liao X; Mehrpour M; Hao X; Chen Q
FASEB J; 2006 Oct; 20(12):2147-9. PubMed ID: 16935937
[TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
Gottlieb AJ; Anderson JR; Ginsberg SJ; Bloomfield CD; Norton L; Barcos M; Peterson BA; Nissen N; Henderson ES; Holland JF
Cancer; 1990 Nov; 66(9):1888-96. PubMed ID: 1699653
[TBL] [Abstract][Full Text] [Related]
19. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance.
Oliver CL; Miranda MB; Shangary S; Land S; Wang S; Johnson DE
Mol Cancer Ther; 2005 Jan; 4(1):23-31. PubMed ID: 15657350
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
Seki R; Ohshima K; Fujisaki T; Uike N; Kawano F; Gondo H; Makino S; Eto T; Moriuchi Y; Taguchi F; Kamimura T; Tsuda H; Ogawa R; Shimoda K; Yamashita K; Suzuki K; Suzushima H; Tsukazaki K; Higuchi M; Utsunomiya A; Iwahashi M; Imamura Y; Tamura K; Suzumiya J; Yoshida M; Abe Y; Matsumoto T; Okamura T
Cancer Sci; 2009 Oct; 100(10):1842-7. PubMed ID: 19656156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
